Skip to main content
Quest Diagnostics

White paper - GLP-1 Receptor Agonists and Precision Medicine

Cardiometabolic White paper

GLP-1 receptor agonists – A case for precision

In the competitive field of diabetes management and weight control, GLP-1 receptor agonists (GLP-I RA) have emerged as a cornerstone therapy, demonstrating significant benefits for broad patient populations. However, this success story has unfolded largely without the nuanced approach of precision medicine.

 

This whitepaper is free and can be downloaded and read at your convenience.

A woman standing and holding her bike

Discover the transformative role of diagnostic labs in metabolic management

Together, we can look forward to a future where metabolic treatments are as personalized as the patients they serve.

"GLP-1 Receptor Agonists – A case for precision" examines this class of therapeutics, advocating for a shift towards more individualized treatment paradigms.

By acknowledging the current one-size-fits-all model, the paper sets the stage for a discussion on integrating precision medicine principles to enhance the therapeutic efficacy and patient experience associated with GLP-I RA. As we look beyond the aggregate success, our focus is to dissect the potential of these drugs when tailored to the unique genetic and molecular profiles of individuals, which could revolutionize the standard of care in diabetes and obesity management.

We chart the agonists' ascent from the initial struggle to the pinnacle of therapeutic success, unraveling the science behind their effectiveness and the real-world impact of their application. From the pioneering once-daily injections to the groundbreaking once-weekly treatments, and now, to the forefront of convenience with the first oral pill, this narrative is not just a scientific overview but a strategic blueprint for the future.

But what lies ahead in the GLP-I RA space is perhaps the most exciting part. We propose a precision medicine framework as the key to unlocking further potential, addressing the challenges of efficacy, delivery, and expanded indications. This white paper outlines a practical approach to aligning drug development with individual patient profiles, maximizing therapeutic effects, and minimizing adverse outcomes.

The opportunity for collaboration in this dynamic field is immense. We invite pharmaceutical partners and industry innovators to download "GLP-1 Receptor Agonists – A case for precision" to consider insights that could shape the next wave of precision therapeutics.

Get the full white paper and be part of the precision medicine revolution.

Discover how we can redefine the management of metabolic disorders for the better. Let's talk!

696

* indicates required

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.